CencoraCOREarnings & Financial Report
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment.
COR Q1 2026 Key Financial Metrics
Revenue
$85.9B
Gross Profit
$3.1B
Operating Profit
$760.4M
Net Profit
$559.6M
Gross Margin
3.6%
Operating Margin
0.9%
Net Margin
0.7%
YoY Growth
13.9%
EPS
$2.87
Financial Flow
Cencora Q1 2026 Financial Summary
Cencora reported revenue of $85.9B for Q1 2026, with a net profit of $559.6M (0.7% margin). Cost of goods sold was $82.9B, operating expenses totaled $2.3B.
Key Financial Metrics
| Total Revenue | $85.9B |
|---|---|
| Net Profit | $559.6M |
| Gross Margin | 3.6% |
| Operating Margin | 0.9% |
| Report Period | Q1 2026 |
Cencora Annual Revenue by Year
Cencora annual revenue history includes year-by-year totals (for example, 2025 revenue was $322.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $322.7B |
| 2024 | $298.4B |
| 2023 | $269.6B |
| 2022 | $240.7B |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.24B | $74.24B | $81.49B | $75.45B | $80.66B | $80.66B | $85.93B | $85.93B |
| YoY Growth | 10.9% | 10.9% | 12.8% | 10.3% | 8.7% | 8.7% | 5.5% | 13.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $66.77B | $67.10B | $69.05B | $71.19B | $73.96B | $76.59B | $78.36B | $78.36B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $925.2M | $645.9M | $226.6M | $1.01B | $1.98B | $1.51B | $1.91B | $1.91B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.48B | $1.00B | $-2.72B | $3.35B | $109.2M | $3.13B | $-2.31B | $-2.31B |
Other Health Care Companies
CAH
Cardinal Health
Revenue
$65.6B
Net Profit
$467.0M
HSIC
Henry Schein
Revenue
$3.3B
Net Profit
$101.0M
MCK
McKesson Corporation
Revenue
$106.2B
Net Profit
$1.2B
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M
AMGN
Amgen
Revenue
$9.9B
Net Profit
$1.3B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M